Phase II, prospective, open-label study of a weekly schedule of irinotecan in patients with advanced colorectal cancer.

被引：0
|
作者：
Casinello, J
Dorta, J
Aguiar, J
Pérez-Carrión, J
Castellanos, J
Valladares, J
Sevilla, J
Belón, J
Fernández, J
Casal, J
机构：
[1] H Meixoeiro, Pontevedra, Spain
[2] H del Bierzo, Leon, Spain
[3] H Virgen de las Nieves, Granada, Spain
[4] H Virgen de la Victoria, Malaga, Spain
[5] H Juan Canalejo, La Coruna, Spain
[6] H Xeral Cies, Pontevedra, Spain
[7] H Princesa, Madrid, Spain
[8] H Gran Canarias, Madrid, Spain
[9] Na Sa Candelaria, Tenerife, Spain
[10] H Guadalajara, Tenerife, Spain
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
198P
引用
收藏
页码：46 / 46
页数：1
相关论文
共 50 条
  • [41] Prospective clinical study phase IIa open-label and not randomized of efficacy and toxicity of weekly paclitaxel chemotherapy in patients with advanced esophagogastric adenocarcinoma
    Diaz, C.
    Calderillo-Ruiz, G.
    Herrers, M.
    Ramos-Ramirez, M.
    Ruiz-Garcia, F.
    Takahashi, A.
    Calderillo, V.
    Horacio, L.
    ANNALS OF ONCOLOGY, 2019, 30 : 93 - 93
  • [42] Phase I study of weekly schedule of oxaliplatin, high-dose leucovorin and infusional fluorouracil in pretreated patients with advanced colorectal cancer.
    Rosati, G
    Rossi, A
    Manzione, L
    ANNALS OF ONCOLOGY, 2000, 11 : 56 - 57
  • [43] Phase I study of weekly schedule of oxaliplatin, high-dose leucovorin and infusional fluorouracil in pretreated patients with advanced colorectal cancer.
    Rosati, G
    Rossi, A
    Bilancia, D
    Manzione, L
    ANNALS OF ONCOLOGY, 2000, 11 : 74 - 74
  • [44] Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: an open-label, multicenter Phase I study
    Saunders, M.
    Van Cutsem, E.
    Wilson, R.
    Peeters, M.
    Smith, R.
    Godwood, A.
    Oliver, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [45] A dose attenuated schedule of irinotecan and capecitabine in combination with celecoxib in advanced colorectal cancer.
    El-Rayes, B. F.
    Shields, A. F.
    Vaishampayan, U.
    Heilbrun, L. K.
    Zalupski, M. M.
    Philip, P. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 166S - 166S
  • [46] A phase II study of oxaliplatin reintroduction in patients pretreated with oxaliplatin and irinotecan for advanced colorectal cancer (RE-OPEN study).
    Suenaga, Mitsukuni
    Mizunuma, Nobuyuki
    Matsusaka, Satoshi
    Shinozaki, Eiji
    Ozaka, Masato
    Ogura, Mariko
    Chin, Keisho
    Yamaguchi, Toshiharu
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [47] A phase II open-label study of vandetanib in patients with locally advanced or metastatic hereditary medullary thyroid cancer
    Haddad, R. I.
    Krebs, A. D.
    Vasselli, J.
    Paz-Ares, L. G.
    Robinson, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [48] Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer
    Aparicio, J
    Vicent, JM
    Maestu, I
    Garcerá, S
    Busquier, I
    Bosch, C
    Llorca, C
    Díaz, R
    Fernández-Martos, C
    Galán, A
    ANNALS OF ONCOLOGY, 2003, 14 (07) : 1121 - 1125
  • [49] An open-label expanded access study of trifluridine/tipiracil for metastatic colorectal cancer.
    Mayer, Robert J.
    Grothey, Axel
    Hochster, Howard S.
    Cohen, Steven J.
    Vukovic, Vojislav M.
    Makris, Lukas
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [50] "Poker" schedule of weekly alternating 5-fluorouracil, irinotecan, bevacizumab, and oxaliplatin (FIR-B/FOX) in advanced colorectal cancer: A phase II study
    Santomaggio, A.
    Ricevuto, E.
    Cannita, K.
    Bruera, G.
    Tudini, M.
    Baldi, P. Lanfiuti
    Mancini, M.
    Porzio, G.
    Marchetti, P.
    Ficorella, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345